JPS61210034A - 関節症治療剤 - Google Patents
関節症治療剤Info
- Publication number
- JPS61210034A JPS61210034A JP5035785A JP5035785A JPS61210034A JP S61210034 A JPS61210034 A JP S61210034A JP 5035785 A JP5035785 A JP 5035785A JP 5035785 A JP5035785 A JP 5035785A JP S61210034 A JPS61210034 A JP S61210034A
- Authority
- JP
- Japan
- Prior art keywords
- crosslinked
- arthropathy
- remedy
- physiological saline
- crosslinking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 5
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 239000002504 physiological saline solution Substances 0.000 abstract description 18
- 150000001875 compounds Chemical class 0.000 abstract description 17
- 208000012659 Joint disease Diseases 0.000 abstract description 14
- 208000036487 Arthropathies Diseases 0.000 abstract description 12
- 239000000243 solution Substances 0.000 abstract description 10
- 239000004593 Epoxy Substances 0.000 abstract description 9
- 238000004132 cross linking Methods 0.000 abstract description 9
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 abstract description 7
- 150000003839 salts Chemical class 0.000 abstract description 7
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract description 5
- 102000001974 Hyaluronidases Human genes 0.000 abstract description 5
- 239000003431 cross linking reagent Substances 0.000 abstract description 5
- 229960002773 hyaluronidase Drugs 0.000 abstract description 5
- 239000003960 organic solvent Substances 0.000 abstract description 5
- 239000002244 precipitate Substances 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 abstract description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000012530 fluid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 210000001179 synovial fluid Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 2
- PXKLMJQFEQBVLD-UHFFFAOYSA-N bisphenol F Chemical compound C1=CC(O)=CC=C1CC1=CC=C(O)C=C1 PXKLMJQFEQBVLD-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- 206010061430 Arthritis allergic Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- -1 impropatol Chemical compound 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5035785A JPS61210034A (ja) | 1985-03-15 | 1985-03-15 | 関節症治療剤 |
| US06/729,558 US4716224A (en) | 1984-05-04 | 1985-05-02 | Crosslinked hyaluronic acid and its use |
| DE85303183T DE3583963D1 (en) | 1984-05-04 | 1985-05-03 | New crosslinked hyaluronic acid prods. |
| EP85303183A EP0161887B1 (en) | 1984-05-04 | 1985-05-03 | Crosslinked hyaluronic acid and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5035785A JPS61210034A (ja) | 1985-03-15 | 1985-03-15 | 関節症治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61210034A true JPS61210034A (ja) | 1986-09-18 |
| JPH0574571B2 JPH0574571B2 (enrdf_load_stackoverflow) | 1993-10-18 |
Family
ID=12856644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5035785A Granted JPS61210034A (ja) | 1984-05-04 | 1985-03-15 | 関節症治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61210034A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04261664A (ja) * | 1990-07-09 | 1992-09-17 | Biomatrix Inc | 生体適合性粘彈性ゲルスラリー、その製法と用途 |
| JP2004536624A (ja) * | 2001-03-13 | 2004-12-09 | フィリップス ハイドロコロイド リサーチ リミテッド | 不飽和ガス雰囲気中での固体照射により得られる新規なバイオポリマー |
| KR101250846B1 (ko) | 2005-07-04 | 2013-04-05 | 주식회사 엘지생명과학 | 히알루론산 가교물의 제조방법 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2910248A1 (en) | 2006-12-06 | 2015-08-26 | Seikagaku Corporation | Pharmaceutical agent having long-lasting effect of treating arthritic disorders |
-
1985
- 1985-03-15 JP JP5035785A patent/JPS61210034A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04261664A (ja) * | 1990-07-09 | 1992-09-17 | Biomatrix Inc | 生体適合性粘彈性ゲルスラリー、その製法と用途 |
| JP2004536624A (ja) * | 2001-03-13 | 2004-12-09 | フィリップス ハイドロコロイド リサーチ リミテッド | 不飽和ガス雰囲気中での固体照射により得られる新規なバイオポリマー |
| KR101250846B1 (ko) | 2005-07-04 | 2013-04-05 | 주식회사 엘지생명과학 | 히알루론산 가교물의 제조방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0574571B2 (enrdf_load_stackoverflow) | 1993-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kleinman et al. | Amyloid syndromes associated with hemodialysis | |
| US4716224A (en) | Crosslinked hyaluronic acid and its use | |
| US6083933A (en) | Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution | |
| AP476A (en) | Eliminating maximum adjacent cut specification restrictions for telescoping pins | |
| DE69424731T2 (de) | Antiulcerogenes Mittel und Adhäsionsinhibitor für Helicobacter pylori | |
| US5910489A (en) | Topical composition containing hyaluronic acid and NSAIDS | |
| JPH06506248A (ja) | 新規な非抗凝固剤ヘパリン誘導体 | |
| Lumlertgul et al. | Furosemide and dopamine in malarial acute renal failure | |
| HU225967B1 (en) | Process for producing of pharmaceutical compositions for the topical treatment of analgetic drug | |
| JPH0223526B2 (enrdf_load_stackoverflow) | ||
| BR9910179A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para tratar uma doença ou condição mediada por fator xa em um animal de sangue quente | |
| RU2021812C1 (ru) | Средство для лечения артрологических заболеваний | |
| US6103704A (en) | Therapeutic methods using hyaluronic acid | |
| JPH02108624A (ja) | 抗ｈｉｖ作用を有するヘパリンフラグメント及びフラクション | |
| JPS61210034A (ja) | 関節症治療剤 | |
| JP5026791B2 (ja) | 医療用化合物あるいは医療用製品を作成するための生体適合性ポリマーの使用方法 | |
| TW200425892A (en) | Composition and its therapeutic use | |
| CN106692179B (zh) | 关节腔注射用含低分子量黄原胶的药物制剂及其制备方法 | |
| JP5025045B2 (ja) | 多硫酸化多糖類によるｔｉｍｐ産生の亢進 | |
| JP2501551B2 (ja) | 架橋ヒアルロン酸 | |
| JP4210330B2 (ja) | ヒアルロン酸レセプター結合剤、およびその使用方法 | |
| DE69826653T2 (de) | Bpc peptid salze mit organ-schützender aktivität, deren herstellung und therapeutische verwendung | |
| EP4400125A1 (en) | Sol-gel transition of 6-arm peg hydrogel over time | |
| CA2089621A1 (en) | Formulations containing hyaluronic acid | |
| RU2235550C2 (ru) | Лекарственное средство бионормализующего действия и способ его получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |